| Description | LEK 8829 is a dopamine D2 receptor antagonist and D1 receptor agonist. |
| Synonyms | LEK8829, LEK-8829 |
| molecular weight | 415.51 |
| Molecular formula | C21H25N3O4S |
| CAS | 145204-78-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Milivojevic N, Krisch I, Sket D, Zivin M. The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):576-82. Epub 2004 May 7. PubMed PMID: 15138661. 2. Zivin M, Sprah L, Sket D. Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine. Eur J Pharmacol. 1998 May 22;349(2-3):151-7. PubMed PMID: 9671092. 3. Zivin M, Sprah L, Sket D. The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions. Br J Pharmacol. 1996 Nov;119(6):1187-96. PubMed PMID: 8937722; PubMed Central PMCID: PMC1915887. 4. Glavan G, Sket D, Zivin M. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats. Mol Pharmacol. 2002 Feb;61(2):360-8. PubMed PMID: 11809861. |